Scintilla Pharma to buy Semnur Pharma
Scintilla Pharmaceuticals Inc, a subsidiary of Sorrento Therapeutics Inc, said Aug 15 that it agreed to buy Semnur Pharmaceuticals Inc for an initial payment of $60 million. Scintilla may also pay another $140 million in cash to Semnur's equity holders upon achievement of certain development, product approval and commercial milestones. Semnur, a specialty pharmaceutical company, is backed by Canaan Partners, Frazier Healthcare and Vivo Capital.
16 August 2016•5 mins read
